

W Kimryn Rathmell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4781645/publications.pdf>

Version: 2024-02-01

105
papers

13,271
citations

66343

42
h-index

33894

99
g-index

114
all docs

114
docs citations

114
times ranked

17353
citing authors

#	ARTICLE	IF	CITATIONS
1	Sunitinib and Axitinib increase secretion and glycolytic activity of small extracellular vesicles in renal cell carcinoma. <i>Cancer Gene Therapy</i> , 2022, 29, 683-696.	4.6	4
2	The therapeutic implications of immunosuppressive tumor aerobic glycolysis. <i>Cellular and Molecular Immunology</i> , 2022, 19, 46-58.	10.5	39
3	Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase. <i>Nature Chemical Biology</i> , 2022, 18, 360-367.	8.0	20
4	Pearls of wisdom for aspiring physician-scientist residency applicants and program directors. <i>JCI Insight</i> , 2022, 7, .	5.0	5
5	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	7.0	12
6	Spatial models of tumour evolution. <i>Nature Ecology and Evolution</i> , 2022, 6, 26-27.	7.8	1
7	Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. <i>BMC Cancer</i> , 2022, 22, 497.	2.6	13
8	Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 2957-2995.	1.6	97
9	Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. <i>World Journal of Urology</i> , 2021, 39, 2409-2415.	2.2	28
10	Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. <i>Nature Reviews Nephrology</i> , 2021, 17, 245-261.	9.6	278
11	Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 167-175.	1.9	4
12	Association of the neutrophil to eosinophil ratio with response to immunotherapy-based combinations in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 341-341.	1.6	0
13	Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1475.	3.7	10
14	Cell-programmed nutrient partitioning in the tumour microenvironment. <i>Nature</i> , 2021, 593, 282-288.	27.8	491
15	A cytoskeletal function for PBRM1 reading methylated microtubules. <i>Science Advances</i> , 2021, 7, .	10.3	17
16	Neuronal SETD2 activity links microtubule methylation to an anxiety-like phenotype in mice. <i>Brain</i> , 2021, 144, 2527-2540.	7.6	17
17	Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. <i>Cell</i> , 2021, 184, 2988-3005.e16.	28.9	166
18	Molecular determinants for α -tubulin methylation by SETD2. <i>Journal of Biological Chemistry</i> , 2021, 297, 100898.	3.4	11

#	ARTICLE	IF	CITATIONS
19	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. <i>Cancer</i> , 2021, 127, 3957-3966.	4.1	11
20	Pushing the boundaries with collision collaboration: the marriage of ideas. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	0
21	Integrative computational immunogenomic profiling of cortisol-secreting adrenocortical carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 10061-10072.	3.6	6
22	Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. <i>Biomarker Research</i> , 2021, 9, 80.	6.8	16
23	Upcycling the TCA cycle—rewiring tumour-associated fibroblasts. <i>Nature Metabolism</i> , 2021, 3, 1439-1440.	11.9	0
24	Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. <i>New England Journal of Medicine</i> , 2021, 385, 2036-2046.	27.0	274
25	The Huntingtin-interacting protein SETD2/HYPB is an actin lysine methyltransferase. <i>Science Advances</i> , 2020, 6, .	10.3	29
26	Fine-Needle Aspiration-Based Patient-Derived Cancer Organoids. <i>IScience</i> , 2020, 23, 101408.	4.1	39
27	PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. <i>Nature Communications</i> , 2020, 11, 2135.	12.8	114
28	COVID-19 impact on early career investigators: a call for action. <i>Nature Reviews Cancer</i> , 2020, 20, 357-358.	28.4	48
29	Beyond glycolysis: Hypoxia signaling as a master regulator of alternative metabolic pathways and the implications in clear cell renal cell carcinoma. <i>Cancer Letters</i> , 2020, 489, 19-28.	7.2	23
30	Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC). <i>Clinical Genitourinary Cancer</i> , 2020, 18, 378-386.e1.	1.9	15
31	Modeling clear cell renal cell carcinoma and therapeutic implications. <i>Oncogene</i> , 2020, 39, 3413-3426.	5.9	86
32	Macrophages Promote Aortic Valve Cell Calcification and Alter STAT3 Splicing. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, e153-e165.	2.4	24
33	Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. <i>JCI Insight</i> , 2020, 5, .	5.0	11
34	DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer. <i>JCI Insight</i> , 2020, 5, .	5.0	41
35	CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. <i>JCI Insight</i> , 2020, 5, .	5.0	52
36	The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. <i>ELife</i> , 2020, 9, .	6.0	168

#	ARTICLE	IF	CITATIONS
37	Disruptions in the realm of medical science. <i>Journal of Clinical Investigation</i> , 2020, 130, 2731-2732.	8.2	0
38	<i>SETD2</i> loss sensitizes cells to PI3K \hat{I}^2 and AKT inhibition. <i>Oncotarget</i> , 2019, 10, 647-659.	1.8	7
39	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 1-6.	1.9	60
40	Transformation to academic leadership: The role of mentorship and executive coaching.. <i>Consulting Psychology Journal</i> , 2019, 71, 141-160.	0.8	16
41	Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers. <i>Journal of Clinical Investigation</i> , 2019, 129, 442-451.	8.2	76
42	The 2019 Nobel Prize honors fundamental discoveries in hypoxia response. <i>Journal of Clinical Investigation</i> , 2019, 130, 4-6.	8.2	17
43	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 23, 313-326.e5.	6.4	523
44	Set2 methyltransferase facilitates cell cycle progression by maintaining transcriptional fidelity. <i>Nucleic Acids Research</i> , 2018, 46, 1331-1344.	14.5	23
45	High Frequency of Ovarian Cyst Development in <i>Vhl;Snf5</i> Mice. <i>American Journal of Pathology</i> , 2018, 188, 1510-1516.	3.8	0
46	Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1588-1593.	1.6	39
47	Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. <i>Journal of Clinical Oncology</i> , 2018, 36, 3540-3546.	1.6	41
48	Systematic Review: ClearCode 34 – A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC). <i>Kidney Cancer</i> , 2018, 2, 23-29.	0.4	23
49	Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. <i>Cell</i> , 2018, 175, 1780-1795.e19.	28.9	445
50	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2018, 4, 1721.	7.1	1,625
51	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. <i>Science</i> , 2018, 361, 290-295.	12.6	134
52	Epigenetic modifiers: activities in renal cell carcinoma. <i>Nature Reviews Urology</i> , 2018, 15, 599-614.	3.8	68
53	<i>SETD2</i> Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma. <i>Cancer Research</i> , 2018, 78, 3135-3146.	0.9	48
54	Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. <i>Theranostics</i> , 2018, 8, 141-155.	10.0	33

#	ARTICLE	IF	CITATIONS
55	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	30.7	900
56	Endogenous retrovirus expression is associated with response to immune checkpoint pathway in clear cell renal cell carcinoma. <i>JCI Insight</i> , 2018, 3, .	5.0	128
57	Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 4804-4820.	8.2	210
58	Balancing dual demands on the physician-scientist workforce. <i>Journal of Clinical Investigation</i> , 2018, 128, 3204-3205.	8.2	5
59	Strategies to overcome therapeutic resistance in renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 102-110.	1.6	35
60	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , 2017, 31, 181-193.	16.8	532
61	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. <i>Oncologist</i> , 2017, 22, 286-292.	3.7	54
62	Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. , 2017, 5, 1.		68
63	Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. <i>BJU International</i> , 2017, 120, 782-792.	2.5	68
64	HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. <i>Cancer Research</i> , 2017, 77, 5313-5326.	0.9	19
65	Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?. <i>Cancer</i> , 2017, 123, 200-209.	4.1	30
66	A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2017, 1, 83-88.	0.4	4
67	Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 825-832.	3.8	25
68	Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. <i>JCI Insight</i> , 2017, 2, .	5.0	257
69	Renal Medullary Carcinoma: Establishing Standards in Practice. <i>Journal of Oncology Practice</i> , 2017, 13, 414-421.	2.5	52
70	Untangling ccRCC prognosis with SLINKY. <i>Oncotarget</i> , 2017, 8, 18620-18621.	1.8	1
71	Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. <i>Clinical Cancer Research</i> , 2016, 22, 5605-5616.	7.0	19
72	AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival. <i>Cell Metabolism</i> , 2016, 23, 649-662.	16.2	195

#	ARTICLE	IF	CITATIONS
73	Rest ASSUREd, much can be learned from adjuvant studies in renal cancer. <i>Nature Reviews Nephrology</i> , 2016, 12, 317-318.	9.6	7
74	Methylated α -tubulin antibodies recognize a new microtubule modification on mitotic microtubules. <i>MABs</i> , 2016, 8, 1590-1597.	5.2	15
75	Dual Chromatin and Cytoskeletal Remodeling by SETD2. <i>Cell</i> , 2016, 166, 950-962.	28.9	204
76	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. <i>Cancer Immunology Research</i> , 2016, 4, 820-822.	3.4	63
77	Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation. <i>Journal of Biological Chemistry</i> , 2016, 291, 21283-21295.	3.4	64
78	Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. <i>Molecular Cancer Research</i> , 2016, 14, 589-598.	3.4	29
79	Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression. <i>Clinical Cancer Research</i> , 2016, 22, 2950-2959.	7.0	21
80	Management of Indeterminate Cystic Kidney Lesions: Review of Contrast-enhanced Ultrasound as a Diagnostic Tool. <i>Urology</i> , 2016, 87, 1-10.	1.0	23
81	Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 122.e1-122.e7.	1.6	23
82	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 135-145.	27.0	1,040
83	Ror2 as a Therapeutic Target in Cancer. , 2015, 150, 143-148.		80
84	Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 386.e1-386.e6.	1.6	15
85	HIF1 α and HIF2 α Exert Distinct Nutrient Preferences in Renal Cells. <i>PLoS ONE</i> , 2014, 9, e98705.	2.5	13
86	ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2014, 66, 77-84.	1.9	234
87	Renal cell carcinoma. <i>BMJ, The</i> , 2014, 349, g4797-g4797.	6.0	509
88	Reply to Alexander S. Parker, Brad C. Leibovich, Jeanette E. Eckel-Passow, John C. Cheville's Letter to the Editor re: Samira A. Brooks, A. Rose Brannon, Joel S. Parker, et al. ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma. <i>Eur Urol</i> 2014;66:77â€“84. <i>European Urology</i> , 2014, 66, e92.	1.9	0
89	The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. <i>Cancer Cell</i> , 2014, 26, 319-330.	16.8	665
90	Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Databaseâ€”UNC GOLD. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 32.e1-32.e9.	1.6	8

#	ARTICLE	IF	CITATIONS
91	Expression of Ror2 Mediates Invasive Phenotypes in Renal Cell Carcinoma. PLoS ONE, 2014, 9, e116101.	2.5	20
92	Receptor Tyrosine Kinase-like Orphan Receptor 2 (Ror2) Expression Creates a Poised State of Wnt Signaling in Renal Cancer. Journal of Biological Chemistry, 2013, 288, 26301-26310.	3.4	29
93	Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncology, The, 2013, 14, 159-167.	10.7	383
94	In Vivo HIF-Mediated Reductive Carboxylation Is Regulated by Citrate Levels and Sensitizes VHL-Deficient Cells to Glutamine Deprivation. Cell Metabolism, 2013, 17, 372-385.	16.2	280
95	State of the Science: An Update on Renal Cell Carcinoma. Molecular Cancer Research, 2012, 10, 859-880.	3.4	142
96	Recent updates in renal cell carcinoma. Current Opinion in Oncology, 2010, 22, 250-256.	2.4	31
97	Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes and Cancer, 2010, 1, 152-163.	1.9	283
98	Neoadjuvant treatment of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 69-73.	1.6	8
99	HIF-1 Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma. Cancer Cell, 2008, 14, 435-446.	16.8	441
100	High-Dose-Intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review. Urology, 2008, 72, 659-663.	1.0	43
101	VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Review of Anticancer Therapy, 2008, 8, 63-73.	2.4	63
102	von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2 signaling and splenic erythropoiesis. Journal of Clinical Investigation, 2007, 117, 3879-89.	8.2	102
103	Renal cell carcinoma. Current Opinion in Oncology, 2004, 16, 247-252.	2.4	9
104	HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma. Anticancer Research, 2004, 24, 167-9.	1.1	22
105	Ligand-independent integrin beta1 signaling supports lung adenocarcinoma development. JCI Insight, 0, , .	5.0	8